AREXVY

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Italy, Lithuania, United Kingdom, United States

Active ingredients

The drug AREXVY contains one active pharmaceutical ingredient (API):

1 RSVPreF3 antigen

RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells. Read about RSV glycoprotein F antigen

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AREXVY Powder for suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BX05		J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3040399, 3040401
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 041312
Country: FR	Base de données publique des médicaments	Identifier(s): 64431629
Country: IT	Agenzia del Farmaco	Identifier(s): 050751015, 050751027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097246, 1097247
Country: US	FDA, National Drug Code	Identifier(s): 58160-723, 58160-744, 58160-848